How do life sciences companies establish a digital governance that structures IT compliance while remaining operationally effective?
For pharma, biotech, MedTech and IVD companies, we build the governance structures within which regulated IT systems are operated: a complete system inventory, GAMP 5-based criticality assessment, clear system ownership, and IT policies for change control, access and incident management in line with EU GMP Annex 11. The critical point is rarely a single validation project, but the missing structure above it: without documented system ownership and a maintained inventory, validation and data integrity drift apart, and the first thing an audit reveals is that no one is formally accountable for a GMP-relevant system.
Overview
What requirements does regulated IT place on a digital governance?
IT governance across all sectors · GAMP 5, EU GMP Annex 11, FDA 21 CFR Part 11
Last updated: June 13, 2026
As the IT landscape grows, it is no longer the validation of the individual system that determines inspection readiness, but the governance above it: who is the system owner, which systems are GMP-relevant, how are changes controlled. The points at which IT governance in life sciences most often breaks down:
- Unclear responsibilities across IT, QA and the business: EU GMP Annex 11 requires a named system owner and a process owner; without formal assignment, there is no clear compliance accountability for a GMP-relevant system.
- Incomplete system inventory: if it is not documented which systems run in production in the GMP environment, the validation status cannot be demonstrated - the inventory baseline is the prerequisite for any risk-based control in line with GAMP 5.
- Missing or inconsistent change control for IT systems: updates, configuration and infrastructure changes without an impact assessment invalidate the validated state that Annex 11 requires across the entire lifecycle.
- IT risk management without a consistent framework: if risks are assessed per project rather than across the portfolio, no comparable prioritization emerges - GAMP 5 calls for an end-to-end risk-based approach rather than isolated, case-by-case assessment.
- Data integrity described only in SOPs: audit trail, access control and authorization concepts in line with Annex 11 and FDA 21 CFR Part 11 must be technically configured and verifiable from a governance perspective, not merely asserted in a policy.
Services
How we support you
IT governance framework & policies
Build-out of an IT governance framework with an IT policy, change control procedure for IT systems, incident management and access control policy, integrated into the existing QMS. Deliverable: a policy set that withstands scrutiny against Annex 11 with defined responsibilities.
Software lifecycle management
Structured control of software versions, patch and update strategy, and end-of-life planning for GMP-critical systems with impact assessment. Deliverable: a lifecycle overview with update and sunset planning for each system.
How we work together
What it comes down to
A growing IT landscape does not make the individual validation the challenge, but rather the structure above it. Three layers have to fit together in the right order: first the system inventory, which makes visible in the first place which systems process GxP data in production. On top of that the GAMP 5 criticality assessment, which sets the validation scope for each system and thereby prevents a standard system from being treated like a bespoke development or a critical system from being under-validated. And only above that the system ownership and the IT policies for change control, access and incident management in line with the EU GMP Guidelines Annex 11. Whoever reverses this order and starts with policies before the inventory is in place is writing rules for systems that no one fully knows.
This is exactly where we come in: the maintained inventory with assigned ownership is the prerequisite for ensuring that computer system validation and data integrity in line with Annex 11 and FDA 21 CFR Part 11 do not drift apart. The most common finding in an audit is not a missing test protocol, but a missing formal accountability - a GMP-relevant system for which IT, QA and the business each believe the others are responsible. Governance closes this gap at the root, before it becomes visible as an individual finding.
Our approach
Our approach
Step
Result
Capture the system inventory
A complete, documented inventory of all production IT systems with assigned owners.
Assess criticality
GAMP 5-based classification with GxP criticality and derived validation scope for each system.
Assign ownership
Defined system and process ownership across IT, QA and the business for every GMP-relevant system.
Set up policies
An IT governance framework with change control, access and incident policies, integrated into the QMS.
Control risks
A portfolio-wide risk register with a prioritized action plan and ongoing tracking.
Operate the lifecycle
Established update, patch and end-of-life control with impact assessment for critical systems.
Common pitfalls
Where projects commonly fail
The system inventory is created once and never maintained.
New systems, migrations and decommissioned legacy systems bypass the inventory; in an audit, the gap between the documented state and live operations becomes apparent, and the validation status of individual systems can no longer be demonstrated.
System owner and IT administrator are confused.
The system owner carries the business and compliance accountability under Annex 11; the administrator operates the system technically. Without this separation, no one is formally responsible for validation status and regulatory conformity.
Change control for IT systems exists only for the application, not for the infrastructure.
Operating system upgrades, database patches and virtualization changes without an impact assessment invalidate the validated state that Annex 11 requires across the lifecycle - a frequent finding in supposedly stable systems.
Data integrity is described in policies but not implemented in the configuration.
A disableable audit trail or shared user accounts contradict the requirements under Annex 11 and FDA 21 CFR Part 11, even if the SOP claims otherwise.
Legacy systems without an end-of-life plan remain in operation.
Software without vendor support no longer receives security patches; without a sunset or mitigation plan in lifecycle management, a permanent IT and compliance risk arises that only becomes visible when an incident occurs.
Supply Chain & Technical Operations
Do any of these pitfalls apply to you?
In a first call we assess your situation and say what needs clarifying first in your case. Without obligation, reply usually within one working day.
FAQ
Frequently asked questions
Sources
- EU GMP Guidelines Annex 11 (Computerised Systems) - primary text
- FDA 21 CFR Part 11 (Electronic Records; Electronic Signatures) - primary text
- GAMP 5 (ISPE) - A Risk-Based Approach to Compliant GxP Computerised Systems
- PIC/S PI 041 - Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Latest insights
All insights →Regulations & standards considered
- EU GMP Guidelines Annex 11 (Computerised Systems)
- FDA 21 CFR Part 11 (Electronic Records; Electronic Signatures)
- GAMP 5 (ISPE Good Automated Manufacturing Practice, A Risk-Based Approach to Compliant GxP Computerised Systems)
- PIC/S PI 041 (Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments)
- ISO/IEC 27001 (Information Security Management Systems)
Related topics
Computer System Validation (CSV) →
CSV as the element that puts governance into operational practice on a per-system basis
21 CFR Part 11 & Data Integrity →
Audit trail and electronic signatures in line with Annex 11 and 21 CFR Part 11
Risk Management →
Risk-based prioritization of the IT system landscape in detail
Digitalization in Life Sciences →
Digital transformation on a robust governance foundation
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences